James Crowe
Faculty Member
Last active: 3/31/2019

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.

Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE, Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, Wittek AE, Casey R, Eichelberger M, Thumar B, Randolph VB, Udem SA, Chanock RM, Murphy BR
J Infect Dis. 2000 182 (5): 1331-42

PMID: 11010838 · DOI:10.1086/315859

A live-attenuated, intranasal respiratory syncytial virus (RSV) candidate vaccine, cpts-248/404, was tested in phase 1 trials in 114 children, including 37 1-2-month-old infants-a target age for RSV vaccines. The cpts-248/404 vaccine was infectious at 104 and 105 plaque-forming units in RSV-naive children and was broadly immunogenic in children >6 months old. Serum and nasal antibody responses in 1-2 month olds were restricted to IgA, had a dominant response to RSV G protein, and had no increase in neutralizing activity. Nevertheless, there was restricted virus shedding on challenge with a second vaccine dose and preliminary evidence for protection from symptomatic disease on natural reexposure. The cpts-248/404 vaccine candidate did not cause fever or lower respiratory tract illness. In the youngest infants, however, cpts-248/404 was unacceptable because of upper respiratory tract congestion associated with peak virus recovery. A live attenuated RSV vaccine for the youngest infant will use cpts-248/404 modified by additional attenuating mutations.

MeSH Terms (13)

Antibodies, Viral Breast Feeding Child, Preschool Enzyme-Linked Immunosorbent Assay Humans Immunization Immunoglobulin A Infant Respiratory Syncytial Viruses Temperature Vaccines, Attenuated Viral Vaccines Virus Shedding

Connections (1)

This publication is referenced by other Labnodes entities:

Links